Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지

A Domestic Outbreak of Bacterial Dysentery Caused by Extended-Spectrum β-Lactamase(ESBL)-producing Shigella sonnei

집단 발생한 Extended-spectrum β-lactamase(ESBL) 생산 Shigella sonnei 감염에 의한 세균성 이질에 관한 연구

  • Lim, Hyun Taek (Department of Pediatrics College of Medicine, Konkuk University) ;
  • Lee, So Hee (Department of Pediatrics College of Medicine, Konkuk University) ;
  • Lee, Jung Hwa (Department of Pediatrics College of Medicine, Konkuk University) ;
  • Kim, Jeong Eun (Department of Pediatrics College of Medicine, Konkuk University) ;
  • Kim, Kyo Sun (Department of Pediatrics College of Medicine, Konkuk University) ;
  • Jeong, Eun Ju (Department of Microbiology College of Medicine, Konkuk University) ;
  • Lee, Seung Hyun (Department of Microbiology College of Medicine, Konkuk University) ;
  • Kang, Chang Gyu (Local Corporation Chungju Medical Center) ;
  • Hong, Seong Jin (Department of Pediatrics College of Medicine, Konkuk University)
  • 임현택 (건국대학교 의과대학 소아과학교실) ;
  • 이소희 (건국대학교 의과대학 소아과학교실) ;
  • 이정화 (건국대학교 의과대학 소아과학교실) ;
  • 김정은 (건국대학교 의과대학 소아과학교실) ;
  • 김교순 (건국대학교 의과대학 소아과학교실) ;
  • 정은주 (건국대학교 의과대학 미생물학교실) ;
  • 이승현 (건국대학교 의과대학 미생물학교실) ;
  • 강창규 (지방공사 충주의료원) ;
  • 홍성진 (건국대학교 의과대학 소아과학교실)
  • Received : 2005.06.20
  • Accepted : 2005.08.05
  • Published : 2005.10.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose : An outbreak of ESBL-producing Shigella sonnei enteritis was unprecedented not only in Korea but throughout the world in the past. We intended to devise a management guideline for ESBL-producing shigellosis based on analysis of clinical manifestations and response to therapy. Methods : We analyzed 103 patients who were admitted to the hospital with acute GI symptoms and were shown positive result for S. sonnei on stool culture. We performed sensitivity test to the antibiotics and DNA sequencing of ESBL gene in the isolated S. sonnei colonies. In addition, we retrospectively analyzed their clinical characteristics, laboratory results, and clinical and microbiological responses to the antibiotics. Results : Among the clinical manifestations, fever was the most frequent(96.1%), followed by diarrhea(93.2%), abdominal pain(76.7%), headache(71.8%), vomiting(65.0%), and nausea(41.7%). The fever was sustained for average of 2.0 days and diarrhea for 3.9 days. Watery diarrhea was the most common(69%) followed by mucoid(26%), and bloody stool(5%). On peripheral blood smear, leukocytosis was noted in 53.4% of patients, and 78.6% of patients tested positive for serum CRP response. On stool direct smear, 11.7% of patients showed more than 50 WBCs/HPF, and 9.7% of patients between 5 to 20 WBCs/HPF. Stool occult blood was positive in 71% of patients. Production of CTX-M-14 type ESBL was reported for all S. sonnei strains isolated from this outbreak. Microbiological eradication rates to various antibiotics were as follows : 100%(9/9) to ciprofloxacin, 100% 5/5) to azithromycin, 6.9%(5/72) to cefdinir, 0%(0/8) to ceftriaxone, 12.5%(1/8) to ceftizoxime, 0%(0/ 8) to TMP/SMX, 42.9%(3/7) to ampicillin/sulbactam, 20%(1/5) to amoxicillin/clavulanic acid, and 68.8 %(11/16) to imipenem/cilastatin. Conclusion : It is presumed that azithromycin can be an attractive option for the treatment of ESBL-producing S. sonnei enteritis in pediatric population, given its cost-effectiveness and safety. Although ciprofloxacin is another cost-effective agent, its use in pediatric population may be a bit too premature.

목 적 : ESBL 생산 S. sonnei에 의한 장염의 대규모 발생은 과거 국내는 물론 세계에서도 유래를 찾아볼 수 없었다. 저자들은 집단 발생한 ESBL 생산 S. sonnei에 의한 장염 환자의 임상적 특징과 치료에 대한 반응 등을 분석하여 ESBL 생산 S. sonnei 감염증에 대한 치료 지침을 마련하는데 도움이 되고자 한다. 방 법 : 연구 대상은 2004년 11월 충주 ${\bigcirc}{\bigcirc}$초등학교를 중심으로 집단 발생한 급성 장염 환자 중 분변 배양 검사상 S. sonnei가 검출되어 치료받은 환자 103명을 대상으로 하였다. 환자에서 분리된 S. sonnei에 대해 항생제 감수성 검사와 DNA 염기 서열 검사를 시행하였고, 환자들의 임상적 특징과 검사 소견, 그리고 항생제에 대한 반응 등을 후향적으로 분석하였다. 결 과 : 임상 증상은 발열 96.1%, 설사 93.2%, 복통 76.7%, 두통 71.8%, 구토 65.0%, 그리고 구역 41.7% 순으로 나타났다. 발열은 평균 2.0일간 지속되었고, 설사는 평균 3.9일간 지속되었다. 설사의 양상은 수양성 설사는 69%, 점액성 설사는 26%, 그리고 혈변은 5%에서 관찰되었다. 말초 혈액 검사에서 백혈구 증다증을 보이는 경우는 53.4%이었고, 혈청 검사에서 CRP 양성을 보이는 경우는 78.6%이었다. 대변 직접 도말 검사에서 백혈구가 고배율 당 50개 이상인 경우가 11.7%, 그리고 5-20개인 경우 9.7%이었다. 대변 잠혈 반응은 71%에서 양성이었다. 본 유행에서 분리된 ESBL의 유형은 염기 서열을 분석한 결과 CTX-M-14 유형으로 밝혀졌다. 항생제 투여에 대한 미생물학적 치료 결과는 ciprofloxacin 투여자 중 100%(9/9), azithromycin 투여자 중 100%(5/5), cefdinir 투여자 중 6.9%(5/72), ceftriaxone 투여자 중 0%(0/8), ceftizoxime 투여자 중 12.5%(1/8), TMP/SMX 투여자 중 0%(0/8), ampicillin/sulbactam 투여자 중 42.9%(3/7), amoxicillin/clavulanic acid 투여자 중 20%(1/5), 그리고 imipenem/cilastatin 투여자 중 68.8%(11/16)에서 추적 검사상 음전 되었다. 결 론 : 소아에서 발생한 ESBL 생산 S. sonnei에 의한 세균성 이질에 대한 항생제 선택에서 비용-효과 면이나 안전성 면에서 azithromycin이 매력적인 일차 선택약일 수 있을 것으로 사료된다. Ciprofloxacin은 비용-효과 면에서는 우수한 약제일 수는 있으나 소아에서의 사용은 아직 이르다고 생각된다.

Keywords

References

  1. The Korea Center for Disease Control and Prevention. Recent trends in national notifiable diseases occurrence based on the data of 2003. Communicable Diseases Monthly Report 2004;15:129-37
  2. Kim SH, Kim JY, Kang YH, Park YK, Lee BK. Occurrence of extended-spectrum beta-lactamases in members of the genus Shigella in the Republic of Korea. J Clin Microbiol 2004;42:5264-9 https://doi.org/10.1128/JCM.42.11.5264-5269.2004
  3. The Korea Center for Disease Control and Prevention. The first domestic outbreak of ESBL producing Shigella sonnei. Communicable Diseases Monthly Report 2004;15:252
  4. Ho PL, Shek RH, Chow KH, Duan RS, Mak GC, Lai EL, et al. Detection and characterization of extended-spectrum beta-lactamases among bloodstream isolates of Enterobacter spp. in Hong Kong, 2000-2002. J Antimicrob Chemother 2005;55:326-32
  5. MEGA. molecular evolutionary genetics analysis[computer program]. version 1.01. Pennsylvania State University, University Park; 1993.
  6. The Korea Center for Disease Control and Prevention. The outbreak of ESBL producing Shigella sonnei. Communicable Diseases Monthly Report 2005;16:1-5
  7. Cleary TG. Shigella. In : Feigin RD, Cherry JD, Demmler GJ, Kaplan SL, editors. Textbook of pediatric infectious diseases. 5th ed. Philadelphia : WB Saunders Co, 2004:1459-69
  8. Dupont HL. Shigella species(Bacillary dysentery). In : Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 6th ed. Philadelphia : Elsevier Churchill Livingstone Co, 2004:2655-61
  9. Thielman NM, Guerrant RL. Clinical practice. Acute infectious diarrhea. N Engl J Med 2004;350:38-47 https://doi.org/10.1056/NEJMcp031534
  10. Guerrant RL, Van Gilder T, Steiner TS, Thielman NM, Slutsker L, Tauxe RV, et al. Practice guidelines for the management of infectious diarrhea. Clin Infect Dis 2001;32:331-51 https://doi.org/10.1086/318514
  11. Salam MA, Bennish ML. Therapy for shigellosis. I. Randomized double-blind trial of nalidixic acid in childhood shigellosis. J Pediatr 1988;113:901-7 https://doi.org/10.1016/S0022-3476(88)80029-5
  12. Bennish ML, Salam MA, Haider R, Barza M. Therapy for shigellosis. II. Randomized, double-blind comparison of ciprofloxacin and ampicillin. J Infect Dis 1990;162:711-6 https://doi.org/10.1093/infdis/162.3.711
  13. Bennish ML, Salam MA, Khan WA, Khan AM. Treatment of shigellosis : III. Comparison of one- or two-dose ciprofloxacin with standard 5-day therapy. A randomized, blinded trial. Ann Intern Med 1992;117:727-34 https://doi.org/10.7326/0003-4819-117-9-727
  14. Salam MA, Seas C, Khan WA, Bennish ML. Treatment of shigellosis : IV. Cefixime is ineffective in shigellosis in adults. Ann Intern Med 1995;123:505-8 https://doi.org/10.7326/0003-4819-123-7-199510010-00005
  15. Khan WA, Seas C, Dhar U, Salam MA, Bennish ML. Treatment of shigellosis : V. Comparison of azithromycin and ciprofloxacin. A double-blind, randomized, controlled trial. Ann Intern Med 1997;126:697-703 https://doi.org/10.7326/0003-4819-126-9-199705010-00004
  16. Prado D, Liu H, Velasquez T, Cleary TG. Comparative efficacy of pivmecillinam and cotrimoxazole in acute shigellosis in children. Scand J Infect Dis 1993;25:713-9 https://doi.org/10.3109/00365549309008568
  17. Salam MA, Dhar U, Khan WA, Bennish ML. Randomized comparison of ciprofloxacin suspension and pivmecillinam for childhood shigellosis. Lancet 1998;352:522-7 https://doi.org/10.1016/S0140-6736(97)11457-X
  18. Helvaci M, Bektaslar D, Ozkaya B, Yaprak I, Umurtak B, Ertugrul A. Comparative efficacy of cefixime and ampicillin-sulbactam in shigellosis in children. Acta Paediatr Jpn 1998;40:131-4 https://doi.org/10.1111/j.1442-200X.1998.tb01896.x
  19. Shanks GD, Smoak BL, Aleman GM, Oundo J, Waiyaki PG, Dunne MW, et al. Single dose of azithromycin or three-day course of ciprofloxacin as therapy for epidemic dysentery in Kenya. Acute dysentery study group. Clin Infect Dis 1999;29:942-3 https://doi.org/10.1086/520469
  20. Kabir I, Butler T, Khanam A. Comparative efficacies of single intravenous doses of ceftriaxone and ampicillin for shigellosis in placebo-controlled trial. Antimicrob Agents Chemother 1986;29:645-8 https://doi.org/10.1128/AAC.29.4.645
  21. Martin JM, Pitetti R, Maffei F, Tritt J, Smail K, Wald ER. Treatment of shigellosis with cefixime : two days vs. five days. Pediatr Infect Dis J 2000;19:522-6 https://doi.org/10.1097/00006454-200006000-00006
  22. Oldfield EC 3rd, Wallace MR, The role of antibiotics in the treatment of infectious diarrhea. Gastroenterol Clin North Am 2001;30:817-36 https://doi.org/10.1016/S0889-8553(05)70212-0
  23. Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, et al. Bloodstream infections due to extended spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae : risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 2004;48:4574-81 https://doi.org/10.1128/AAC.48.12.4574-4581.2004
  24. Nakamura T, Komatsu M. Susceptibility of ESBL-producing Escherichia coli and Klebsiella pneumoniae to various antibiotic agents. Jpn J Antibiot 2005;58:1-10 https://doi.org/10.1038/ja.2005.1
  25. The Korea Center for Disease Control and Prevention. Extended-spectrum ${\beta}$-lactamase. Communicable Diseases Monthly Report 2001;12:45-8
  26. Pitout JD, Sanders CC, Sanders WE Jr. Antimicrobial resistance with focus on ${\beta}$-lactam resistance in gramnegative bacilli. Am J Med 1997;103:51-9 https://doi.org/10.1016/S0002-9343(97)00044-2
  27. Jacoby GA. Epidemiology of extended-spectrum ${\beta}$-lactamases. Clin Infect Dis 1998;27:81-3 https://doi.org/10.1086/514644
  28. Rice L. Evolution and clinical importance of extended-spectrum ${\beta}$-lactamases. Chest 2001;119(2 Suppl):391S-6S https://doi.org/10.1378/chest.119.2_suppl.391S
  29. Bush K. New ${\beta}$-lactamases in gram-negative bacteria : diversity and impact on the selection of antimicrobial therapy. Clin Infect Dis 2001;32:1085-9 https://doi.org/10.1086/319610
  30. Colodner R. Extended-spectrum ${\beta}$-lactamases : a challenge for clinical microbiologists and infection control specialists. Am J Infect Control 2005;33:104-7 https://doi.org/10.1016/j.ajic.2004.07.010
  31. Pai H, Choi EH, Lee HJ, Hong JY, Jacoby GA. Identification of CTX-M-14 extended-spectrum ${\beta}$-lactamase in clinical isolates of Shigella sonnei, Escherichia coli, and Klebsiella pneumoniae in Korea. J Clin Microbiol 2001;39:3747-9 https://doi.org/10.1128/JCM.39.10.3747-3749.2001
  32. Neu HC, Saha G, Chin NX. Comparative in vitro activity and ${\beta}$-lactamase stability of FK482, a new oral cephalosporin. Antimicrob Agents Chemother 1989;33:1795-800 https://doi.org/10.1128/AAC.33.10.1795
  33. Chatterjee A, Moland ES, Thomson KS. Cefdinir : An oral alternative to parenteral cephems. Diagn Microbiol Infect Dis 2005;51:259-64 https://doi.org/10.1016/j.diagmicrobio.2004.11.015
  34. Rupp ME, Fey PD. Extended spectrum beta-lactamase(ESBL)-producing Enterobacteriacea : considerations for diagnosis, prevention and drug treatment. Drugs 2003;63:353-65 https://doi.org/10.2165/00003495-200363040-00002
  35. Stapleton P, Wu PJ, King A, Shannon K, French G, Phillips I. Incidence and mechanism of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli. Antimicrob Agents Chemother 1995;39:2478-83 https://doi.org/10.1128/AAC.39.11.2478
  36. Burkhardt JE, Walterspiel JN, Schaad UB. Quinolone arthropathy in animals versus children. Clin Infect Dis 1997;25:1196-204 https://doi.org/10.1086/516119
  37. Hampel B, Hullmann R, Schmidt H. Ciprofloxacin in pediatrics : worldwide clinical experience based on compassionate use-safety report. Pediatr Infect Dis J 1997;16:127-9 https://doi.org/10.1097/00006454-199701000-00036
  38. The Zimbabwe, Bangladesh, South africa(Zimbasa) Dysentery Study Group. Multicenter, randomized, double blind clinical trial of short course versus standard course oral ciprofloxacin for Shigella dysenteriae type 1 dysentery in children. Pediatr Infect Dis J 2002;21:1136-41 https://doi.org/10.1097/00006454-200212000-00010
  39. Jacoby GA, Chow N, Waites KB. Prevalence of plasmid-mediated quinolone resistance. Antimicrob Agents Chemother 2003;47:559-62 https://doi.org/10.1128/AAC.47.2.559-562.2003
  40. Rakita RM, Jacques-Palaz K, Murray BE. Intracellular activity of azithromycin against bacterial enteric pathogens. Antimicrob Agents Chemother 1994;38:1915-21 https://doi.org/10.1128/AAC.38.9.1915